GGrantIndex
Sort

82,697 grants matching vaccine development

Contributions of durable, high-avidity T-cell responses to protection achieved using the Opti-FliP vaccine regimen

$1,260,330
Dennis J Hartigan-O'Connor · University Of California At Davis · P01 · FY2025 · AI

Dynamics of Protein Assemblies by Analytical Ultracentrifugation

$1,260,310
Peter Schuck · National Institute Of Biomedical Imaging And Bioengineering · ZIA · FY2023 · EB

Non-Human Primate Core (NHP Core)

$1,260,301
Koen K Van Rompay · Duke University · P01 · FY2016 · AI

Antiviral therapeutics for flavivirus infections

$1,260,044
Chelsea Byrd Olsen · Siga Technologies, Inc. · R01 · FY2012 · AI

Multicenter AIDS Cohort Study

$1,260,025
Charles R Rinaldo · University Of Pittsburgh At Pittsburgh · U01 · FY2009 · AI

University of California, Berkeley (UCB)/University of *

$1,260,000
Arthur L. Reingold · University Of California Berkeley · D43 · FY2006 · TW

Response Therapies for MDR-TB

$1,259,826
Ian M Orme · Colorado State University · U01 · FY2010 · AI

Developing an inactivated whole cell H. pylori vaccine

$1,259,746
Emergent Biosolutions · U01 · FY2005 · AI

Aurum Clinical Trials Unit

$1,258,716
Gavin John Churchyard · Aurum Institute Npc · UM1 · FY2022 · AI

CTL and HIV Polymorphisms in Heterosexual Transmission

$1,258,577
Eric Hunter · Emory University · R01 · FY2006 · AI

High Precision System Analysis of Infant Immune Responses

$1,258,393
Pablo J. Sanchez · Research Inst Nationwide Children'S Hosp · U01 · FY2021 · AI

Laboratory Studies of Human Respiratory Syncytial Virus and Other Pneumoviruses

$1,258,386
Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Clinical Trials of Vaccines for Respiratory Syncytial Virus and Related Viruses

$1,258,384
Ursula Buchholz · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI

Vaccines to counter emerging antibiotic resistance (R01AI138970)

$1,258,174
Wendy L Picking · University Of Missouri-Columbia · R01 · FY2022 · AI

Stimulant Pharmacotherapy: Noradrenergic Targets

$1,257,829
Thomas Richard Kosten · Baylor College Of Medicine · P50 · FY2012 · DA

Computational biology scientific research support component

$1,257,775
Thomas B Kepler · Duke University · UM1 · FY2018 · AI

Human Monoclonal Antibodies and Antibody-Guided Nanoparticles

$1,257,527
Dimiter S Dimitrov · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA

UCSF-Stanford Center of Excellence in Regulatory Science and Innovation

$1,257,392
Kathleen M Giacomini · University Of California, San Francisco · U01 · FY2024 · FD

St. Jude/Memphis IMPAACT Clinical Trials Unit

$1,257,366
Patricia Michele Flynn · St. Jude Children'S Research Hospital · U01 · FY2007 · AI

Harnessing B cells for TB vaccine development to improve therapy of TB and TB-HIV coinfection

$1,257,077
Martin Alfons Gengenbacher · Hackensack University Medical Center · R01 · FY2025 · AI

Recombinant Vaccines for Prevention of AIDS and Other Diseases

$1,256,929
Bernard Moss · National Institute Of Allergy And Infectious Diseases · Z01 · FY2008 · AI

SPORE in Skin Cancer

$1,256,837
Wistar Institute · P50 · FY2001 · CA

CTSA INFRASTRUCTURE FOR AIDS RESEARCH

$1,256,490
Barry Coller · Rockefeller University · UL1 · FY2007 · RR

Synthesis of Therapeutic Agents for Treatment of Infectious Diseases

$1,256,450
Mark Middleton · Starks Associates, Inc. · N01 · FY2021 · AI

Cervical, Anal & Oral HPV Persistence/Adolescent Girls

$1,256,429
Angela Diaz · Icahn School Of Medicine At Mount Sinai · R01 · FY2023 · AI